Dispelling Cancer Vaccines Myths and Misconceptions

As interest grows in cancer vaccines, patients may be eager for breakthroughs that could prevent recurrence or even stop cancer from developing. But according to Keith Knutson, a cancer vaccine researcher at the Mayo Clinic, many common assumptions about these treatments don’t reflect where the science is heading. In a recent interview for the CURE “Speaking Out” video series on behalf of the Cancer Vaccine Coalition, Knutson emphasized that cancer vaccines are not, and likely will never be, one-size-fits-all.

“I think the biggest misconception is that we’re going to develop a vaccine that’s going to be useful for all the women that have breast cancer, and all the men that have breast cancer,” Knutson said. Unlike infectious disease vaccines, which work the same way for large populations, cancer vaccines must account for the biological diversity of tumors.

Breast cancer alone illustrates the challenge.

“There are many subtypes of breast cancer, so it’s a very heterogeneous disease,” he said. Because of that complexity, researchers will need different vaccines for different tumor types, and likely even more customization within those categories. “One size fits all isn’t going to work. One for each subtype of breast cancer may be effective, but I think what’s going to be more important is that we develop capabilities of rapidly making vaccines for each individual that comes through the door.”

What makes this personalization necessary, Knutson explained, is the highly individual nature of cancer biology. Tumors arise from abnormal protein expression and genetic changes that vary widely from person to person.

“Breast cancer, as well as other cancers, is really just a malignancy, but it’s associated with aberrant expression … of all these different proteins,” he said. “Each individual’s tumors are very unique. They fall into certain categories, but they each have different mutations. They each have different proteins that they express.”

Advances in genomic testing and vaccine technology are making such tailored approaches possible. Tumor sequencing can now identify the specific proteins a patient’s cancer expresses. New manufacturing tools allow researchers to design and produce personalized vaccines far faster than before.

“We now have the capabilities of really identifying what those proteins are at the individual level, and with new modern technologies for developing vaccines, we can rapidly synthesize vaccines that are specific for a patient’s tumor,” Knutson said.

Still, the misconception that cancer vaccines will resemble traditional immunizations persists, likely because infectious disease vaccines are the closest point of comparison for most people. Knutson cautioned against expecting the same model.

For patients, understanding this distinction is key to setting realistic expectations. Personalized vaccines may offer promising new treatment options, but they will require careful matching to each individual’s tumor makeup. As research continues, Knutson and others hope that tailoring vaccines to unique cancer profiles will one day make prevention and long-term control possible.

For now, he said, the focus is on educating patients and the public: cancer vaccines are coming, but they won’t come in a one-size-fits-all form.

Editor’s note: Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.